{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:42:25Z","timestamp":1794854545800,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To prospectively evaluate the safety and efficacy of avanafil, a novel PDE5 inhibitor, in men with mild to severe ED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, double-blind, Phase 3 trial, 646 subjects were randomized to receive avanafil (50 mg, 100 mg, 200 mg) or placebo throughout a 12-week treatment period. Subjects were instructed to take study drug 30 minutes prior to initiation of sexual activity. At least a 12-hour separation time between doses was required; no restrictions were placed on food or alcohol intake.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Improvement in erectile function (EF) was measured by Sexual Encounter Profile questions 2 and 3 (SEP2 and SEP3) and by the EF domain of the International Index of Erectile Function (IIEF) questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean change in percentage of successful sexual attempts (SEP2 and SEP3) and IIEF-EF domain score significantly favored all doses of avanafil over placebo (P \u2264 0.001). Secondary analyses demonstrated achievement of successful intercourse by subjects within 15 minutes of dosing. Of the 300 sexual attempts made during this interval, 64% to 71% were successful in avanafil-treated subjects compared with 27% in placebo-treated subjects. Successful intercourse was also demonstrated &amp;gt;6 hours post dosing, with 59% to 83% of the 80 sexual attempts successful in avanafil-treated subjects compared with 25% of placebo-treated subjects. The most commonly reported adverse events in subjects taking avanafil included headache, flushing, and nasal congestion; there were no drug-related serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Following 12 weeks of avanafil treatment without food or alcohol restrictions, significant improvements in sexual function were observed with all 3 doses of avanafil compared with placebo. Successful intercourse was observed as early as 15 minutes and &amp;gt;6 hours after dosing in some subjects. Avanafil was generally well tolerated for the treatment of ED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2011.02629.x","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:15:55Z","timestamp":1326759355000},"page":"1122-1133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction"],"prefix":"10.1093","volume":"9","author":[{"given":"Irwin","family":"Goldstein","sequence":"first","affiliation":[{"name":"Sexual Medicine, Alvarado Hospital , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"McCullough","sequence":"additional","affiliation":[{"name":"Albany College of Medicine , Albany, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeRoy A.","family":"Jones","sequence":"additional","affiliation":[{"name":"Urology San Antonio Research , San Antonio, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne J.","family":"Hellstrom","sequence":"additional","affiliation":[{"name":"Tulane University , New Orleans, LA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Bowden","sequence":"additional","affiliation":[{"name":"VIVUS, Inc. , Mountain View, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"DiDonato","sequence":"additional","affiliation":[{"name":"VIVUS, Inc. , Mountain View, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Trask","sequence":"additional","affiliation":[{"name":"VIVUS, Inc. , Mountain View, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley W.","family":"Day","sequence":"additional","affiliation":[{"name":"VIVUS, Inc. , Mountain View, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,4,1]]},"reference":[{"key":"2024032600264546800_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1743-6109.2004.10106.x","article-title":"Epidemiology\/risk factors of sexual dysfunction","volume":"1","author":"Lewis","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600264546800_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032600264546800_bb0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(05)67900-1","article-title":"Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study","volume":"163","author":"Johannes","year":"2000","journal-title":"J Urol"},{"key":"2024032600264546800_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","article-title":"Prevalence and risk factors for erectile dysfunction in the US","volume":"120","author":"Selvin","year":"2007","journal-title":"Am J Med"},{"key":"2024032600264546800_bb0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1098-3597(05)80045-6","article-title":"The underlying pathophysiology and causes of erectile dysfunction","volume":"7","author":"Wyllie","year":"2005","journal-title":"Clin Cornerstone"},{"key":"2024032600264546800_bb0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinte.166.2.207","article-title":"Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population","volume":"166","author":"Saigal","year":"2006","journal-title":"Arch Intern Med"},{"key":"2024032600264546800_bb0040","doi-asserted-by":"crossref","first-page":"9M","DOI":"10.1016\/S0002-9149(03)00824-5","article-title":"Overview of phosphodiesterase 5 inhibition in erectile dysfunction","volume":"92","author":"Rosen","year":"2003","journal-title":"Am J Cardiol"},{"key":"2024032600264546800_bb0045","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int J Impot Res"},{"key":"2024032600264546800_bb0050","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"key":"2024032600264546800_bb0055","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1743-6109.2009.01375.x","article-title":"The ENDOTRIAL study: A spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction","volume":"6","author":"Jannini","year":"2009","journal-title":"J Sex Med"},{"key":"2024032600264546800_bb0060","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/j.1743-6109.2009.01447.x","article-title":"2009 update on phosphodiesterase type 5 inhibitor therapy part 2: Updates on optimal utilization for sexual concerns and rare toxicities in this class","volume":"6","author":"Shindel","year":"2009","journal-title":"J Sex Med"},{"key":"2024032600264546800_bb0065","first-page":"435","article-title":"Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: Review of the literature","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur J Med Res"},{"key":"2024032600264546800_bb0070","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"key":"2024032600264546800_bb0075","author":"Data on file"},{"key":"2024032600264546800_bb0080","article-title":"Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction","author":"Kaufman","journal-title":"Presented at the Scientific Meeting of the Sexual Medicine Society of North America, Inc. November 17\u201320, 2005: New York City, NY: Abstract #68; 2005"},{"key":"2024032600264546800_bb0085","first-page":"1196","article-title":"Rigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunction","volume":"316","author":"Lewis","year":"2004","journal-title":"J Urol"},{"key":"2024032600264546800_bb0090","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2024032600264546800_bb0095","first-page":"S11","article-title":"Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors","volume":"104","author":"Sussman","year":"2004","journal-title":"J Am Osteopath Assoc"},{"key":"2024032600264546800_bb0100","author":"Cialis [package insert]","year":"2010"},{"key":"2024032600264546800_bb0105","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1743-6109.2006.00273.x","article-title":"Efficacy of tadalafil in men with erectile dysfunction na\u00efve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate","volume":"3","author":"Broderick","year":"2006","journal-title":"J Sex Med"},{"key":"2024032600264546800_bb0110","article-title":"Avanafil for the Treatment of Erectile Dysfunction in Diabetic Men: Results of a Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial","author":"Goldstein","journal-title":"Presented at the 16th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Inc. November 11\u201314, 2010: Miami Beach, FL: Poster #13; 2010"},{"key":"2024032600264546800_bb0115","article-title":"A randomized, double-blind, placebo-controlled, parallel group, multicenter study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing radical prostatectomy","author":"Mulhall","journal-title":"Poster presented at the Cancer Survivorship and Sexual Health Symposium; June 17\u201318, 2011; Washington, DC; 2011"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515339369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515339369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/9\/4\/1122\/47769773\/jsm_9_4_1122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/9\/4\/1122\/47769773\/jsm_9_4_1122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:20:16Z","timestamp":1711401616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/9\/4\/1122\/6886684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,1]]},"published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02629.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.716697812.792003172","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,4]]},"published":{"date-parts":[[2012,4,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double\u2010Blind, Placebo\u2010Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02629.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}